Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
Date:9/10/2007

tly completed Phase Ib cancer study, which showed that the combination of bavituximab with paclitaxel and carboplatin might be especially promising in breast cancer patients. We look forward to assessing bavituximab's potential in this larger trial in women battling metastatic breast cancer."

Tumor response will be evaluated every other month using Response Evaluation Criteria in Solid Tumors (RECIST) parameters. The trial is being conducted according to International Conference on Harmonization (ICH) and Good Clinical Practices (GCP) guidelines.

According to the World Health Organization, metastatic breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that 178,480 U.S. women will be diagnosed with cancer of the breast in 2007 and 40,460 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients, bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity, achieving objective response or disease stabilization in 50% of the evaluable patients. A protocol for a Phase ll trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) is currently undergoing regulatory review in India. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.

Safe Harbor Statement: Statements in this press r
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2008)... Awareness and Bring Hope to Millions,of Children ...e/ -- 133 million children,across the globe are wi...disaster, civil war, and disease. SOS Children,s V...ek by calling attention to the needs of orphans,wo... to:, http://www.prnewswire.com/mnr/soschildrens...
(Date:10/9/2008)...s and Marketing Efforts to Accelerate ... PARK, Calif., Oct. 9 /- Evalve, Inc.... percutaneous repair of cardiac valves,has expand... appointment of,Sean Cleary as senior vice preside...ardson, as vice president of sales., "The additio...
(Date:10/9/2008)...titute, Navigenics, Affymetrix and,Microsoft team ... /- A consortium of health care,tech...a first-of-its-kind,research study to assess the b...ople who choose to receive such screenings to iden...iseases., Sponsored by Scripps Translational Scie...
(Date:10/8/2008)...re-USNewswire/ -- The facts are,overwhelming. Ever...b-Saharan Africa. More than 35,000,000 women, chil...ied of AIDS. The Foundation for Hospices,in Sub-Sa...eir families,find compassion and relief from suffe...ring initiative links African hospices and palliat...
Breaking Medicine Technology:Photos: SOS Children's Villages Observes World Orphan Week, October 5-11, 2008 2Evalve Expands Executive Leadership Team 2Evalve Expands Executive Leadership Team 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 2Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 3Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 4Landmark Research Study is Launched to Assess Impact of Personal Genetic Testing 5In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 1Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 2Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 3Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 4Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 5Data Presented at the American Academy of Neurology Show XP13512 GSK1838262 Significantly Improved Symptoms of Moderate to Severe Primary Restless Leg 1843 6Overuse of Opioids Barbiturates Boosts Chronic Migraine Risk 17140 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 1Migraines Frequency Influences Heart Attack Stroke Risk 17138 2Migraines Frequency Influences Heart Attack Stroke Risk 17138 3Parents stricter with older kids to set example 3A game theory study 17136 1Parents stricter with older kids to set example 3A game theory study 17136 2
...h 20, 2007 /PRNewswire-FirstCall/ --,Alfacell Corp...l to,act as a potent payload in antibody conjugate...ion of the Handbook of Therapeutic,Antibodies. , I... Susanna,Rybak, Ph.D. summarizes preclinical resea... ONCONASE improves in a number of tumor,models, in...
...Enzyme Levels in Two Most Common Mutations, CRANBU...erapeutics, a biopharmaceutical company developing...al chaperones for the,treatment of a range of huma...resent the results of preclinical studies of,Plice...disease at,the of Medical Genetics (ACMG) annual m...
Other Medicine Technology:Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 2Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 3Alfacell's Onconase Highlighted in Latest Edition of Handbook of,Therapeutic Antibodies 4Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 2Amicus Therapeutics Presents Preclinical Data from Studies of,Plicera for Gaucher Disease 3
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...reatment could help prevent future blood clots in ...mboembolism (VTE) affects approximately 2 million ...osis (blood clots common in the thigh and back) an...on in the lung). Despite progress in diagnosis and...
...ion for some patients with large liver tumors. The... //before using lasers to heat and destroy the tum...proves the overall survival of the patients. Radio...nduced thermotherapy (LITT) to heat tumors. The pr...
...on that can be fatal. It is defined as an obstruct... a blood clot, //which blocks a coronary artery. W...onary embolism, a new study shows a new treatment ...inister to patients than the current treatment. Ac...
...f the American Society of Therapeutic Radiology an...beam radiation may be what it takes to relieve pai...d to the bone. More than 160 hospitals and univers...were involved in a study of about 900 men and wome...
Other Medicine News:Health News:Extended Therapy for Blood Clots 2Health News:New Liver Tumor Treatment 2
...w XCD-SX910CR digital camera incorporates a Progre...excellent sensitivity (1280 (H) x 960 (V) SXGA. Wh...ask (commonly called a "Bayer filter") and outputs... converted to a color image on the computer. The c...
...661 is a monochrome " 1.3 Megapixel FireWire camer...s. Desgined to simplify real-time uncompressed vi...A661 provides uncompromising video and digital sti...-A661 is ideal for industrial inspection tasks inv...
...h acclaimed GT-CAPTURE digital camera photomicrogr...ers microscope such as Olympus, Leica, Nikon, and ...sferring images over the Internet easy and fast. F...ormance-proven Nikkor lens. The system records pho...
...0 is a superb stand-alone digital camera with netw...es from local or remote locations. Image acquisiti...amera operates independently or attaches directly ...o capture and transfer images. Sharing images in r...
Medicine Products: